Sometimes a clinical trial works too well to continue. That's the enviable position Praxis Precision Medicines Inc. (PRAX) found itself in Friday, sending shares soaring after the company announced its epilepsy drug relutrigine was so effective that continuing the study would be unethical.
The Data Monitoring Committee recommended halting the EMBOLD study early based on efficacy results. The trial was evaluating relutrigine for treating patients with SCN2A and SCN8A developmental and epileptic encephalopathies, rare and severe forms of epilepsy.
When a drug shows clear benefits in a trial, keeping patients on placebo becomes a problem. That's essentially what happened here, and it's the kind of problem biotech companies dream about having.
FDA Meeting and Regulatory Timeline
The FDA has confirmed a meeting with Praxis in the coming weeks to review the data and map out next steps. The company will decide on timing for filing its New Drug Application after that discussion.
Topline results from EMBOLD are set to be presented Saturday at the American Epilepsy Society Annual Meeting in Atlanta.
Separately, Praxis completed its pre-NDA meeting with the FDA on Thursday, receiving both written feedback and participating in an in-person session. The company has aligned with the agency on what needs to go into the NDA and expects to submit the application in early 2026.
From Overlooked to Blockbuster
HC Wainwright analyst Douglas Tsao thinks investors have been sleeping on relutrigine for too long. He sees the drug as a blockbuster just in the SCN8A and SCN2A patient populations, with potential to expand significantly in the broader developmental and epileptic encephalopathy market being tested in the separate EMERALD study.
The firm anticipates priority review from the FDA, with approval likely next year.
"We can't recall an instance where a biotech company got its first two approvals of drugs developed organically and both with blockbuster potential within a span of just a few months. The success of EMBOLD also significantly derisks and accelerates the development of relutrigine in broader DEEs," the HC Wainwright analyst wrote Friday.
Those are bold words backed by bolder numbers. Tsao increased the probability of success for relutrigine from 60% to 80% and more than tripled projected peak sales from $760 million to $2.8 billion. HC Wainwright maintains its Buy rating on Praxis while raising the price target from $258 to $340.
Building on Previous Success
This isn't Praxis's first impressive clinical readout. Back in August, the company reported topline results from its Phase 2 RADIANT study evaluating vormatrigine, another epilepsy treatment, in patients with focal onset seizures and generalized epilepsy.
That trial demonstrated a median seizure reduction of approximately 56.3%, with 60% of patients achieving at least a 50% reduction in seizures. Strong pipeline momentum across multiple programs is rare in biotech, and investors took notice.
Praxis Precision Medicine shares jumped 30.84% to $248.56 Friday, hitting a new 52-week high as the market digested the implications of a drug that might be too effective to keep testing.
